GLP-1 rebound weight gain cut with structured meals, app

Clinical takeaway: Suggest pairing a GLP-1 halt with meal delivery or a weight loss app, which appears to slow regain. 

Up to half of patients discontinue GLP-1 therapy within a year of starting, often because of cost, insurance limitations, adverse effects, or after reaching a target weight. But weight regain frequently follows treatment discontinuation, and evidence-based approaches to help patients maintain their weight loss remain scarce.

Behavioral interventions have a long history of supporting weight-loss maintenance, making them a natural candidate to address the challenge of post-GLP-1 weight regain. In this randomized pilot trial, researchers tested whether a structured meal program paired with a digital app could help patients maintain their weight loss after discontinuing therapy.

Patients on usual care regained an estimated 10.75% of their body weight over four months. Those given medically tailored meals gained an estimated 3.58% and those using the app 3.60%, about 7 percentage points less in each case, with intervals running from roughly 2 to 12 points. Usual-care patients gained 2.94% per month, versus 0.61% with meals and 0.42% with the app. 

Diet quality, perceived health, and satisfaction did not differ by group. Self-reported adherence scored numerically lower with the app than with usual care, with a wide interval. Participants reported eating an average of 8.08 of 10 weekly meals and using the app 2.8 days per week. 

In the subset with complete prior weight-loss data, adjusting for weight lost on GLP-1 and baseline weight narrowed the difference to 5.83 points with the app and 6.29 with meals. Both stayed statistically significant. 

The pilot randomized 39 adults who had lost more than 10% of their body weight on a GLP-1 to usual care, the commercial app Noom, or medically tailored meals within 30 days of stopping. Meal participants chose 10 dietitian-developed meals per week from a menu of more than 70, delivered to their homes. Home Bluetooth scales tracked weight for four months. Of the 39 paticipants, 34 completed a final weigh-in, including 10 of 14 usual-care patients. Adherence and satisfaction were the primary outcomes, and weight was exploratory. 

NIH and university grants funded the trial, including participant meals and Noom subscriptions. The authors state that Noom had no role in the study's design, conduct, reporting, or interpretation. They also note that a larger follow-up study, funded by a Noom grant awarded after this trial ended, is preparing to recruit participants and will help assess longer-term outcomes beyond the study's 6-month follow-up.

"People invest significant time and effort in improving their health and achieving weight loss," said Kelseanna Hollis-Hansen, corresponding author, Tufts University Food is Medicine Institute. "We need evidence-based strategies to support them if and when they discontinue GLP-1 medication, so they can maintain those gains and continue building long-term health, vitality, and well-being." 

Source: Hollis-Hansen K, et al. (2026 Oct 7) Obes Sci Pract. Preventing Weight Regain After Glucagon-Like Peptide-1 Therapy Discontinuation: A Pilot Randomized Controlled Trial